Literature DB >> 33518535

Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21).

Bo Kyung Koo1.   

Abstract

Entities:  

Year:  2021        PMID： 33518535      PMCID： PMC8017332          DOI： 10.7570/jomes20133

Source DB:  PubMed          Journal:  J Obes Metab Syndr        ISSN： 2508-6235


× No keyword cloud information.
  10 in total

1.  Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms.

Authors:  Jennifer N Cooper; Jeanine M Buchanich; Ada Youk; Maria Mori Brooks; Emma Barinas-Mitchell; Molly B Conroy; Kim Sutton-Tyrrell
Journal:  Atherosclerosis       Date:  2012-05-30       Impact factor: 5.162

Review 2.  Effect of weight loss induced by energy restriction on measures of arterial compliance: A systematic review and meta-analysis.

Authors:  K S Petersen; P M Clifton; N Lister; J B Keogh
Journal:  Atherosclerosis       Date:  2016-01-29       Impact factor: 5.162

Review 3.  Effect of weight loss on pulse wave velocity: systematic review and meta-analysis.

Authors:  Kristina S Petersen; Natalie Blanch; Jennifer B Keogh; Peter M Clifton
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-20       Impact factor: 8.311

4.  Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.

Authors:  Ju-Young Hong; Keun-Young Park; Jong-Dai Kim; Won-Min Hwang; Dong-Mee Lim
Journal:  J Obes Metab Syndr       Date:  2020-09-30

5.  Different Relationship Between Physical Activity, Arterial Stiffness, and Metabolic Status in Obese Subjects.

Authors:  Hyung Joon Joo; Sang-A Cho; Jae-Young Cho; Seunghun Lee; Jae Hyung Park; Cheol Woong Yu; Soon Jun Hong; Do-Sun Lim
Journal:  J Phys Act Health       Date:  2017-05-17

6.  Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial.

Authors:  Timothy M Hughes; Andrew D Althouse; Nancy A Niemczyk; Marquis S Hawkins; Allison L Kuipers; Kim Sutton-Tyrrell
Journal:  Cardiovasc Diabetol       Date:  2012-09-22       Impact factor: 9.951

7.  Brachial-ankle pulse wave velocity and metabolic syndrome in general population: the APAC study.

Authors:  Anxin Wang; Zhaoping Su; Xiaoxue Liu; Yuling Yang; Shuohua Chen; Suzhen Wang; Yanxia Luo; Xiuhua Guo; Xingquan Zhao; Shouling Wu
Journal:  BMC Cardiovasc Disord       Date:  2016-11-18       Impact factor: 2.298

8.  How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.

Authors:  Agnes Bosch; Christian Ott; Susanne Jung; Kristina Striepe; Marina V Karg; Dennis Kannenkeril; Thomas Dienemann; Roland E Schmieder
Journal:  Cardiovasc Diabetol       Date:  2019-03-29       Impact factor: 9.951

9.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Authors:  David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-01-29       Impact factor: 9.951

10.  Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.

Authors:  Anna Solini; Livia Giannini; Marta Seghieri; Edoardo Vitolo; Stefano Taddei; Lorenzo Ghiadoni; Rosa Maria Bruno
Journal:  Cardiovasc Diabetol       Date:  2017-10-23       Impact factor: 9.951
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.